56 material Form 8-K filings that 54 companies we cover made with the SEC in November 2023, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Veeco reported third-quarter 2023 revenue of $177.4 million, up from $171.9 million a year earlier, and GAAP net income of $24.6 million ($0.42 per diluted share), up from $15.0 million ($0.27). Its conference presentation raised the 2023 non-GAAP EPS outlook to $1.55 to $1.65 from $1.30 to $1.50, and the fourth-quarter revenue guidance is $155 million to $175 million.
Q3 2023 revenue $177.4 million vs $171.9 million in Q3 2022
GAAP diluted EPS $0.42 vs $0.27; non-GAAP diluted EPS $0.53 vs $0.45
Q4 2023 guidance: revenue $155 million to $175 million; non-GAAP diluted EPS $0.35 to $0.45
2023 non-GAAP EPS outlook raised to $1.55 to $1.65 from $1.30 to $1.50; nine-month GAAP net loss of $52.0 million reflects a $97 million loss on debt extinguishment
Krystal Biotech reported third quarter 2023 results, with net income of $80.7 million, or $2.88 per basic share, compared with a net loss of $29.9 million a year earlier. The result was driven by a $100 million gain from the sale of a Priority Review Voucher, while the company's loss from operations was $26.0 million and its first VYJUVEK product revenue was $8.6 million. Cash, cash equivalents and investments totaled $598.6 million at September 30, 2023.
Q3 2023 net income was $80.7 million, including a $100 million gain from the sale of a Priority Review Voucher.
Q3 2023 product revenues, net were $8.6 million, with 284 VYJUVEK Patient Start Forms received as of the end of the quarter.
Nine-month 2023 net income was $2.2 million, compared with a net loss of $107.9 million for the same period in 2022.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.